AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.58, $0.10 better than the analyst estimate of $1.48. Revenue for the quarter came in at $6.42 billion versus the consensus estimate of $6.32 billion.

GUIDANCE:

AstraZeneca sees FY2019 EPS of $3.50-$3.70.

• Product Sales: A high single-digit percentage increase

The PDF could not be displayed inside the page, click here to open.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.